

Grahame J Elder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/327949/publications.pdf>

Version: 2024-02-01

57
papers

1,999
citations

393982

19
h-index

243296

44
g-index

58
all docs

58
docs citations

58
times ranked

2478
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3â€“4 CKDâ€”results from a placebo-controlled randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 344-351.	0.4	2
2	Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease. , 2022, 32, 58-67.		4
3	Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 59-76.	3.0	16
4	Improving Bone Mineral Density Screening by Using Digital $\text{X}\text{\AA}$ Radiogrammetry Combined With Mammography. <i>JBMR Plus</i> , 2022, 6, e10618.	1.3	1
5	Patients with end-stage kidney disease have markedly abnormal cortical hip parameters by dual-energy X-ray absorptiometry. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 543-550.	0.4	10
6	The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 649-656.	0.4	19
7	Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease. , 2021, 31, 155-163.		2
8	The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)â€”A Systematic Review. <i>Diagnostics</i> , 2021, 11, 772.	1.3	7
9	A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. <i>Endocrine</i> , 2021, 73, 509-529.	1.1	15
10	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. <i>Kidney International</i> , 2021, 100, 502-505.	2.6	10
11	Osteoporosis associated with chronic kidney disease. , 2021, , 1325-1380.		1
12	Radiographic absorptiometry: a step in solving the CKD fracture puzzle. <i>Kidney International</i> , 2020, 98, 826-828.	2.6	0
13	Changes to bone mineral density, the trabecular bone score and hip structural analysis following parathyroidectomy: a case report. <i>BMC Nephrology</i> , 2020, 21, 513.	0.8	4
14	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2653-2666.	3.0	52
15	A rare case of cauda equina syndrome from a brown tumour. <i>Journal of Nephrology</i> , 2020, 33, 1103-1105.	0.9	0
16	Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2020, 51, 201-215.	1.4	24
17	How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. <i>EClinicalMedicine</i> , 2020, 29-30, 100662.	3.2	21
18	Vascular Calcification in CKD. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 226-241.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Outcomes of cinacalcet withdrawal in Australian dialysis patients. <i>Internal Medicine Journal</i> , 2019, 49, 48-54.	0.5	9
20	Laparoscopic partial nephrectomy for Juxtaglomerular apparatus tumour: A rare cause of hypertension. <i>Urology Case Reports</i> , 2019, 26, 100910.	0.1	1
21	Association between Aortic Calcification, Cardiovascular Events, and Mortality in Kidney and Pancreas-Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2019, 50, 177-186.	1.4	23
22	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019, 9, e024382.	0.8	18
23	Health-related quality of life following kidney and simultaneous pancreas kidney transplantation. <i>Nephrology</i> , 2019, 24, 975-982.	0.7	19
24	Role of dietary phosphate restriction in chronic kidney disease. <i>Nephrology</i> , 2018, 23, 1107-1115.	0.7	9
25	Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>The Cochrane Library</i> , 2018, 2018, CD006023.	1.5	82
26	Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. <i>American Journal of Nephrology</i> , 2018, 47, 376-384.	1.4	39
27	Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. <i>Bone</i> , 2018, 114, 14-21.	1.4	26
28	Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. <i>Bone</i> , 2018, 113, 118-123.	1.4	20
29	Changes in bone microarchitecture following kidney transplantation—Beyond bone mineral density. <i>Clinical Transplantation</i> , 2018, 32, e13347.	0.8	9
30	Sex hormone-binding globulin is a biomarker associated with nonvertebral fracture in men on dialysis therapy. <i>Kidney International</i> , 2018, 94, 372-380.	2.6	8
31	Chronic kidney disease mineral and bone disorders; controversies and directions. <i>Nephrology</i> , 2017, 22, 5-8.	0.7	0
32	The role of calcium and non calcium-based phosphate binders in chronic kidney disease. <i>Nephrology</i> , 2017, 22, 42-46.	0.7	12
33	Is there a practical role for bone biopsy in chronic kidney disease?. <i>Nephrology</i> , 2017, 22, 22-26.	0.7	6
34	Calcium-based phosphate binders; down, but not out. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 5-8.	0.4	30
35	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	0.8	25
36	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2016-2017.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Mushroom Clouds for Vitamin D?. Journal of the American Society of Nephrology: JASN, 2016, 27, 1581-1584.	3.0	2
38	Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 232-244.	2.2	143
39	Opportunistic in-hospital screening for kidney disease using the Kidney Health Check. Nephrology, 2014, 19, 693-698.	0.7	5
40	Vascular calcification in patients undergoing kidney and simultaneous pancreas-kidney transplantation. Nephrology, 2014, 19, 275-281.	0.7	11
41	A case report of disabling bone pain after long-term kidney transplantation. Osteoporosis International, 2014, 25, 769-772.	1.3	2
42	Health-related quality of life of patients awaiting kidney and simultaneous pancreas-kidney transplants. Nephrology, 2013, 18, 827-832.	0.7	7
43	Effects of Cholecalciferol on Functional, Biochemical, Vascular, and Quality of Life Outcomes in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1143-1149.	2.2	83
44	Pathophysiology of CKD-MBD. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 128-141.	1.3	2
45	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology, 2012, 17, 433-444.	0.7	42
46	Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. The Cochrane Library, 2011, , CD006023.	1.5	55
47	Calcium supplementation: lessons from the general population for chronic kidney disease and back. Current Opinion in Nephrology and Hypertension, 2011, 20, 369-375.	1.0	9
48	Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2011, 305, 1119.	3.8	580
49	Individualized Therapy to Prevent Bone Mineral Density Loss after Kidney and Kidney-Pancreas Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 117-124.	2.2	27
50	Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases, 2009, 54, 619-637.	2.1	150
51	Review article: Patient-level outcomes: the missing link. Nephrology, 2009, 14, 443-451.	0.7	12
52	Renal Function and Bisphosphonate Safety. Journal of Bone and Mineral Research, 2008, 23, 453-454.	3.1	5
53	Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH-(1-34). CKJ: Clinical Kidney Journal, 2008, 1, 97-99.	1.4	5
54	Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone. Nephrology, 2006, 11, S230-S261.	0.7	34

#	ARTICLE	IF	CITATIONS
55	Parathyroidectomy in the calcimimetic era. <i>Nephrology</i> , 2005, 10, 511-515.	0.7	29
56	Pathophysiology and Recent Advances in the Management of Renal Osteodystrophy. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 2094-2105.	3.1	154
57	Pathogenesis and management of hyperparathyroidism in end-stage renal disease and after renal transplantation. <i>Nephrology</i> , 2001, 6, 155-160.	0.7	0